arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IGC Pharma, Inc.

IGC
$0.18 ▼ -0.01 (-4.09%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

IGC Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $13.8M
Dividend Yield —
Revenue Growth -5.5% ↘
Op. Margin None
ROIC -115.2% ↗
FCF / Share $-0.06 ↗
Trailing P/E —
Price / Book 2.3x
FCF Yield —
Debt / Equity 0.02
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.27M
↓ -5.5% —
Net Income Profit after all expenses
$-7.12M
↑ +45.2% —
Operating Margin Operating profit as % of sales
-168.6%
↓ -85.7% —
FCF / Share Free cash flow per share
$-0.06
↑ +29.3% —
Long-Term Debt Long-term obligations
$134.00K
↓ -2.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↓
7
Financial Health →
47
Cash Quality ↓
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 66 quarters